Description

TERBIFACE 500 MG

Indications

TERBIFACE 500 MG is primarily indicated for the treatment of fungal infections caused by dermatophytes, yeasts, and certain molds. It is effective against conditions such as tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and candidiasis. This medication is often prescribed for patients who have not responded adequately to topical antifungal therapies or in cases where the infection is extensive or recurrent.

Mechanism of Action

TERBIFACE contains the active ingredient terbinafine, which is an allylamine antifungal agent. The primary mechanism of action involves the inhibition of squalene epoxidase, an enzyme crucial for the biosynthesis of ergosterol, a vital component of fungal cell membranes. By disrupting ergosterol synthesis, terbinafine leads to the accumulation of squalene, which is toxic to fungi. This results in the death of the fungal cells and the resolution of the infection.

Pharmacological Properties

TERBIFACE is well-absorbed after oral administration, with peak plasma concentrations occurring within 2 to 4 hours. The bioavailability of terbinafine is approximately 40% to 70%, depending on the presence of food. The drug is highly lipophilic, which allows it to accumulate in skin, nails, and fatty tissues. Terbinafine is primarily metabolized by the liver through the cytochrome P450 system, specifically CYP2D6, and is excreted in urine as metabolites. The half-life of terbinafine is approximately 36 hours, allowing for once-daily dosing in most cases.

Contraindications

TERBIFACE is contraindicated in individuals with a known hypersensitivity to terbinafine or any of its components. It should not be used in patients with severe liver impairment or active liver disease, as terbinafine is extensively metabolized by the liver. Additionally, caution is advised when prescribing to patients with a history of alcohol abuse or those taking medications that can affect liver function.

Side Effects

Common side effects associated with TERBIFACE include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Dermatological reactions may also occur, including rash, pruritus, and urticaria. Rare but serious side effects include hepatotoxicity, which may manifest as jaundice or elevated liver enzymes, and blood dyscrasias such as neutropenia or thrombocytopenia. Patients should be monitored for any signs of severe adverse reactions, particularly during the initial months of therapy.

Dosage and Administration

The recommended dosage of TERBIFACE for adults is 250 mg taken orally once daily for most fungal infections. In cases of onychomycosis (fungal nail infection), a longer treatment duration of 6 to 12 weeks may be necessary, depending on the severity and location of the infection. It is essential to follow the prescribing physician’s instructions and complete the full course of therapy to ensure effective treatment and minimize the risk of recurrence.

Interactions

TERBIFACE may interact with several medications, particularly those that are metabolized by the liver. Strong inducers of CYP450 enzymes, such as rifampicin and phenobarbital, can decrease the plasma concentration of terbinafine, potentially reducing its efficacy. Conversely, inhibitors of CYP450, such as cimetidine, may increase terbinafine levels, leading to an increased risk of side effects. It is crucial for healthcare providers to review a patient’s medication list to avoid potential drug interactions.

Precautions

Before initiating treatment with TERBIFACE, a thorough medical history should be obtained, focusing on liver function and any history of hypersensitivity reactions. Patients with pre-existing liver conditions should be closely monitored throughout therapy. It is also advisable to perform baseline liver function tests and to monitor these tests periodically during treatment. Patients should be counseled about the signs of liver dysfunction and advised to report any unusual symptoms promptly.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of TERBIFACE in treating various fungal infections. In a randomized controlled trial involving patients with onychomycosis, TERBIFACE demonstrated a significantly higher cure rate compared to placebo, with a favorable safety profile. Another study confirmed its effectiveness in treating tinea infections, showing rapid clinical improvement and mycological cure rates. These studies support the use of TERBIFACE as a first-line treatment option for systemic fungal infections.

Conclusion

TERBIFACE 500 MG is an effective antifungal medication indicated for the treatment of various fungal infections. Its unique mechanism of action, pharmacological properties, and clinical efficacy make it a valuable option in the management of dermatophyte and yeast infections. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients are encouraged to adhere to the prescribed treatment regimen and maintain communication with their healthcare provider for optimal outcomes.